Stopping tirzepatide: the economics nobody budgets

What SURMOUNT-4 actually showed

The design was simple and brutal: everyone received tirzepatide for a 36-week lead-in (average loss around a fifth of body weight), then half were switched to placebo. Over the next 52 weeks, the placebo group regained a large majority of what they'd lost — roughly 14% of body weight back — while the continued-tirzepatide group lost several additional points. The lesson clinicians draw is that obesity behaves like a chronic condition: the medication manages it while present, and withdrawal tends to unwind the management. Individuals vary, lifestyle programs blunt regain for some, and stopping is sometimes the right call — but the base rate says budget as if continuation is likely, because for most patients it is.

The three year-two paths, priced

Population-level trial findings; your trajectory is individual and stopping/tapering decisions belong with your prescriber. Prices from our July 2026 dataset.

Why maintenance pricing is the number that matters most

The two-year chart reframes the whole shopping decision. A flat plan runs $186 × 24 = $4,464. A tiered plan that reaches its maintenance band runs roughly $5,148 in year one and $499 × 12 ≈ $5,988 in year two — about $11,100 total, two and a half times the flat path for the identical medication journey. The stop-at-twelve-months line is cheapest in dollars and carries the regain risk the trial quantified. Whatever you choose clinically, choose it on purpose: the worst outcome is drifting into year two on a tiered plan's top band because month one's $279 looked friendly.

The restart problem

Patients who stop and later restart pay a specific set of costs the ads never mention: a fresh consultation, sometimes fresh labs, a return to the 2.5 mg starting dose and the full titration climb (a safety feature, not red tape — tolerability resets), and, on dose-tiered pricing, a second trip through the escalation bands they already paid through once. On flat-rate plans the restart is clinically identical but financially flat. If your honest self-assessment says stopping and restarting is a realistic pattern for you, that asymmetry alone argues for the flat structure — or for the brand vials, where the price attaches to dose strength rather than a program's escalation schedule.

What maintenance actually looks like on the label

One practical detail that shapes year-two budgets: maintenance doesn't necessarily mean the maximum dose. Zepbound's labeled maintenance doses are 5, 10, or 15 mg once weekly, and prescribers individualize among them based on response and tolerability — plenty of patients maintain well at 5 or 10 mg. On flat-rate compounded plans the distinction is financially irrelevant, which is the point. On dose-tiered plans it's the difference between the ~$349–$399 band and the ~$499 band, roughly $1,200–$1,800 per maintenance year. And on LillyDirect vials it determines whether your dose exists in the self-pay lineup at all. Translate your prescriber's maintenance target into each model's price before choosing the model — it's a five-minute conversation that can be worth four figures annually, and it's a conversation the pricing pages are designed not to start.

Budgeting year two like an adult

Treat tirzepatide the way you'd treat any chronic-condition line item: assume continuation at maintenance dose, price it annually ($2,232 flat / ~$6,000 tiered / ~$5,100 vials), pay it with HSA/FSA dollars where eligible, and revisit at each renewal against our current price report. If you and your clinician plan a stop, plan the support around it too — the SURMOUNT-4 curves are averages, not destiny, and structured lifestyle programs are where the counter-examples live. The science journal's regain explainer and SURMOUNT-4 breakdown cover the clinical side in depth.